Last reviewed · How we verify
Daital (ETERSALATE)
Daital (generic name: ETERSALATE) is a drug. It is currently in Phase 2 development.
Daital works by binding to a specific target, but the exact mechanism is unknown.
Daital (Etersalate) is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. Further information on its pharmacokinetics, safety, and efficacy is not available. As a result, it is difficult to provide a comprehensive summary of this compound. More research is needed to understand its potential therapeutic applications and risks.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ETERSALATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and Daital is a key that fits into one of those locks. When it binds, it can either turn the lock on or off, depending on the type of lock and the key's shape. However, since the target is unknown, we can't say exactly how Daital works or what it does when it binds.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daital CI brief — competitive landscape report
- Daital updates RSS · CI watch RSS
Frequently asked questions about Daital
What is Daital?
How does Daital work?
What is the generic name of Daital?
What development phase is Daital in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing